Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer

This study has been terminated.
(Enrollment was far below anticipated participation and there is insufficient data to publish.)
Sponsor:
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
Duke University
ClinicalTrials.gov Identifier:
NCT01207102
First received: September 10, 2010
Last updated: September 17, 2014
Last verified: August 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: June 2014
  Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)